Key facts
- Allotex’s last known valuation is $358.0M (Mar 2018).
- It has raised $46.8M across 1 recorded rounds; the latest was Early Stage VC ($16.7M) in Feb 2018.
- Notable investors include Supernova Invest, Panakes Partners, Exor, Junson Capital, KCK MedTech — 6 tracked in total.
- Allotex has filed 1 Form D with the SEC, most recently Mar 2018 ($16.7M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Allotex
Funding rounds
1 roundsAbout Allotex
Operator of an ophthalmic biologics and device company intended for the treatment of presbyopia, hyperopia and myopia. The company uses precisely-shaped human corneal allografts with a compact excimer laser system to create a permanent, living contact lens or lens insert, enabling medical professionals to offer treatment that has the least invasive for all refractive procedures.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2014
- Employees
- 21
- Website
- allotex.com/
- Ownership
- Privately Held (backing)
Allotex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allotex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allotex in its N-PORT filings yet. We sweep new filings monthly.